Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

Open access
Gritti, Giuseppe, Raimondi, Federico, Bottazzi, Barbara, Ripamonti, Diego, Riva, Ivano, Landi, Francesco, Alborghetti, Leonardo, Frigeni, Marco, Damiani, Marianna, Micò, Caterina, Fagiuoli, Stefano, Lorini, Ferdinando Luca, Gandini, Lucia, Novelli, Luca, Morgan, Jonathan P., Owens, Benjamin M. J., Kanhai, Karan J. K., Reljanovic, Gordana Tonkovic, Rizzi, Marco, Di Marco, Fabiano, Mantovani, Alberto, Rambaldi, Alessandro·2021·Leukemia

Abstract

Abstract Background Severe COVID-19 is characterised by interstitial pneumonia and hyperinflammation, with elevated levels of pro-inflammatory cytokines, such as IL-6. Effective treatments are urgently needed, and IL-6 is a rational target to reduce hyperinflammation. Methods An observational, control cohort, single-centre study initiated at the Papa Giovanni XXIII Hospital in Bergamo, Italy included patients with COVID-19 confirmed by a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus 2 RNA and interstitial pneumonia requiring ventilatory support. Patients were treated with either best supportive care and siltuximab or best supportive care alone. Propensity score matching was applied to minimise differences in baseline covariates between patient cohorts. The main outcome was mortality in siltuximab-treated patients compared with patients in the matched-control cohort. This study ( S iltuximab i n S evere CO VID-19, SISCO) is registered with ClinicalTrials.gov , identifier NCT04322188 . Findings Thirty patients received siltuximab, while 188 control patients received only best supportive care. Siltuximab-treated patients were matched to 30 control patients using the propensity score analysis of baseline covariates. The 30-day mortality rate was significantly lower in the siltuximab-treated than the matched-control cohort patients (HR 0·462, 95% CI 0·221– 0·965); p=0·0399). The mean follow-up was 33·3 days (range 7–58 days) for the siltuximab-treated patients and 22·8 days (range 2–45 days) for the control cohort. Sixteen siltuximab-treated patients were discharged from hospital, four remained on mechanical ventilation, and 10 patients died. Interpretation Patients with rapidly progressing COVID-19 respiratory failure requiring ventilatory support may benefit from treatment with siltuximab to reduce mortality and cytokine-driven hyperinflammation associated with severe disease. These findings require validation in a randomised controlled clinical trial. Funding Papa Giovanni XXIII Hospital and the Italian Association for Cancer Research funded the study. EUSA Pharma supplied siltuximab, and provided funding for data collection, analysis, and development of the publication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-021-01299-x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 210

Metadata

Authors
Gritti, G., Raimondi, F., Bottazzi, B., Ripamonti, D., Riva, I., Landi, F., Alborghetti, L., Frigeni, M., Damiani, M., Micò, C., Fagiuoli, S., Lorini, F. L., Gandini, L., Novelli, L., Morgan, J. P., Owens, B. M. J., Kanhai, K. J. K., Reljanovic, G. T., Rizzi, M., Di Marco, F., Mantovani, A., & Rambaldi, A.
Venue
Leukemia
Published
2021-05-24
Volume
35
Issue
9
Pages
2710-2714
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W3165022701
Cited by
210
References
10
FWCI
9.25
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. https://app.cochat.ai/papers/10.1038/s41375-021-01299-x
The paper
Gritti, G., Raimondi, F., Bottazzi, B., Ripamonti, D., Riva, I., Landi, F., Alborghetti, L., Frigeni, M., Damiani, M., Micò, C., Fagiuoli, S., Lorini, F. L., Gandini, L., Novelli, L., Morgan, J. P., Owens, B. M. J., Kanhai, K. J. K., Reljanovic, G. T., Rizzi, M., . . . Rambaldi, A. (2021). Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia. https://doi.org/10.1038/s41375-021-01299-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.